Skip to content
drillr.ai
Sign up

01276.HK

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN

Also listed · 600276.SH →
HKD 50.70
+0.10%
Ask drillr

  • Nov 1, 2026, 06:51 UTC

    Shifangyun (Shanghai) Technology Co., Ltd. and Jiangsu Hengrui Pharmaceuticals Co., Ltd. signed a strategic cooperation agreement to collaborate on AI-enabled pharmaceutical innovation and patient value across the full lifecycle.

    Source:

  • Oct 30, 2026, 09:07 UTC

    BlackRock, Inc. reduced its H-share holdings in Jiangsu Hengrui Pharmaceuticals from 6.10% to 5.97% on October 27, 2026.

    Source:

  • Oct 28, 2026, 09:40 UTC

    China’s National Medical Products Administration approved clinical trials of HRS-8046 tablets, developed by Chengdu Shengdi Pharmaceutical and Shanghai Hengrui Pharmaceutical, for planned treatment of KRAS G12D-mutated solid tumors.

    Source:

  • Oct 27, 2026, 10:06 UTC

    Hengrui Medicine reported third-quarter net profit of RMB2.458 billion, up 89% year over year, and first-nine-month net profit of RMB6.92 billion, up 20.4%.

    Source:

  • Oct 27, 2026, 10:00 UTC

    China’s National Medical Products Administration approved an additional indication for Hengrui Medicine’s remimazolam tosylate for injection, for sedation during mechanical ventilation in intensive care.

    Source:

  • Oct 26, 2026, 09:00 UTC

    China’s National Medical Products Administration approved clinical trials of SHR-2005 injection in combination regimens for bladder cancer.

    Source:

  • Oct 23, 2026, 01:56 UTC

    China’s National Medical Products Administration approved Hengrui Medicine’s application to conduct clinical trials of its ruiluvelutamide tablets for prostate cancer.

    Source:

  • Oct 22, 2026, 10:17 UTC

    Hengrui Medicine repurchased 150,000 A-shares on October 22, 2026, at RMB 45.55–46.25 per share for approximately RMB 6.9152 million.

    Source:

  • Oct 22, 2026, 09:03 UTC

    Hengrui Medicine said it had repurchased 1.6362 million shares by October 22, 2026, for a total of RMB 73.8849 million.

    Source:

  • Oct 19, 2026, 10:21 UTC

    Jiangsu Hengrui Pharmaceuticals repurchased 203,600 A-shares on October 19, 2026, for approximately RMB 9.4008 million, with the shares intended for an A-share employee shareholding plan.

    Source:

  • Oct 16, 2026, 10:57 UTC

    BlackRock, Inc. reduced its long position in Jiangsu Hengrui Medicine’s H shares from 6.33% to 5.72%.

    Source:

  • Oct 16, 2026, 09:19 UTC

    Hengrui Medicine repurchased 195,000 A-shares on the Shanghai Stock Exchange for RMB 8.9971 million, at RMB 45.60–46.33 per share, for an employee shareholding plan.

    Source:

  • Oct 15, 2026, 09:10 UTC

    BlackRock, Inc. increased its holdings in Hengrui Medicine H shares from 5.69% to 6.31%.

    Source:

  • Oct 2, 2026, 10:03 UTC

    UBS Group reduced its long position in Jiangsu Hengrui Pharmaceuticals H-shares from 5.17% to 4.59% on September 25, according to a Hong Kong Stock Exchange disclosure.

    Source:

  • Sep 29, 2026, 07:15 UTC

    Danish pharmaceutical company Novo signed an exclusive agreement with Chinese company Jiangsu Hengrui Pharmaceuticals for rights to develop, produce and sell a weight loss pill in all markets except China, Hong Kong, Macau and Taiwan.

    Source:

  • Sep 29, 2026, 04:29 UTC

    Hengrui Medicine signed a licensing agreement with Novo Nordisk for HRS-1596.

    Source:

  • Sep 20, 2026, 05:57 UTC

    Hengrui Pharmaceuticals reported R&D spending of 4.605 billion yuan in the first half of 2026, up 18.96% year on year and equal to 29.8% of revenue.

    Source:

  • Sep 20, 2026, 05:57 UTC

    Hengrui Pharmaceuticals reported that in the first half of 2026 its innovative-drug sales revenue rose to 8.809 billion yuan, 63.16% of drug sales revenue, with non-oncology innovative-drug revenue up 73.97%.

    Source:

  • Sep 10, 2026, 06:33 UTC

    Hengrui Medicine held its 2026 interim results briefing on September 10, 2026, where it discussed its pipeline outlook.

    Source:

  • Sep 7, 2026, 10:58 UTC

    Hengrui Medicine announced it will hold an extraordinary general meeting on September 24, 2026 to consider adopting a 2026 H-share plan, and will suspend H-share registration from September 21 to 24, 2026.

    Source:

  • Aug 25, 2026, 09:06 UTC

    GIC Private Limited increased its stake in Hengrui Medicine's H shares from 14.29% to 15.70% on August 20, 2026, with an average purchase price of HKD 50.5655 per share.

    Source:

  • Aug 19, 2026, 11:39 UTC

    Hengrui Medicine announced its first-half 2026 results with revenue of 15.456 billion yuan, down 1.94% year-on-year, and net profit attributable to shareholders of 4.465 billion yuan, up 0.34%.

    Source:

  • Jul 31, 2026, 09:11 UTC

    Capital Group increased its stake in Hengrui Medicine H-shares on July 29, raising its holding from 9.86% to 10.04%, with an average purchase price of 57.9041 HKD.

    Source:

  • Jul 30, 2026, 01:42 UTC

    China's National Medical Products Administration approved four innovative drugs for market launch.

    Source:

  • Jul 28, 2026, 07:25 UTC

    Jiangsu Hengrui Medicine Co., Ltd. established a wholly-owned subsidiary Zhejiang Hengrui Medicine Co., Ltd. in Zhejiang with a registered capital of 50 million yuan.

    Source:

  • Jul 28, 2026, 02:02 UTC

    CSPC Pharmaceutical Group's marketing application for injectable sirolimus (albumin-bound) was accepted by the National Medical Products Administration and granted priority review.

    Source:

  • Jul 28, 2026, 01:36 UTC

    Ascletis Pharma announced that its once-monthly subcutaneous triple agonist peptide ASC37 showed superior weight loss effects in a diet-induced obesity mouse model.

    Source:

  • Jun 5, 2026, 23:32 UTC

    Hengrui Pharma and Kailera Therapeutics presented clinical data for ribupatide at the ADA 2026 conference.

    Source:

  • Jun 1, 2026, 06:00 UTC

    Hengrui Pharma presented more than 90 oncology studies at ASCO 2026, highlighting progress across multiple tumor types.

    Source: